Arexis AB
Division of Biovitrum AB/Arexis AB
www.arexis.com
Latest From Arexis AB
Recent Dealmaking (9/2003)
Summarizing the month in European dealmaking.
CliniGenetics SA
French start-up CliniGenetics SA has devised an integrated pharmacogenomics and bioinformatics technology platform to identify gene and protein targets associated with vascular diseases. The company hopes to use those targets to devise novel therapies and diagnostics.
The Battle For the Bulging
Despite disappointments in the hunt for effective fat-busting drugs, this large and seemingly ever-growing market is encouraging companies to continue to rise to the challenge of a disease that is a host of interacting disorders.
Tackling Diabetes and Obesity
The growing incidence of these diseases, and their complexity, provide opportunities for a number of different approaches
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Scandinavia
-
Sweden
-
Sweden
-
Scandinavia
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Biovitrum AB
- Senior Management
-
Lennart Hansson, PhD, CEO
Vidar Wendel-Hansen, MD, PhD, CBO
Bjorn Lowendadler, Phd, CSO - Contact Info
-
Arexis AB
Phone: (46) 317 491 100
Arvid Wallgrens backe
Göteborg, SE-413 46
Sweden
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Arexis AB
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice